Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease

Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22.

¹ Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.
² GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy.
³ Haematology Section, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
⁴ Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, PN, Italy.
⁵ Department of Haematology, Tor Vergata University, Rome, Italy.
⁶ Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
⁷ Department of Haematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
⁸ Department of Molecular Medicine, Sapienza University, Rome, Italy.

No abstract available

Keywords: 11q deletion; BIRC3 gene; chronic lymphocytic leukaemia; droplet digital PCR; prognosis.

Publication types